# Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)
> Exchange: NSE | Sector: Pharma | ISIN: INE048B01035

## Price
Current Price: ₹209.92
Day Change: -0.91%
52W High: ₹301.8
52W Low: ₹154.9
Market Cap: ₹1,386 Cr

## Valuation
P/E: 32.67
P/B: 5.24
EPS: ₹6.32
Book Value: ₹39.4
Dividend Yield: 1.93%

## Returns
1Y Return: -0.3%

## Profitability
ROE: 16.7%
ROCE: 17.73%
Debt/Equity: 0.03
Revenue Growth: 9.6%
Profit Growth: 23.8%
EBITDA Margin: 20.22%
Operating Margin: 13.77%

## About
Jagsonpal Pharmaceuticals Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Jagsonpal Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- Announcement: Submission Of Letter Of Offer For Buy-Back Upto 16,00,000 Equity Shares
- BSE Filing: Announcement under Regulation 30 (LODR)-Newspaper Publication

## Access
Current tier: anonymous
More history: Register free to see 1 more year.

## Data Freshness
Quote Updated: 2026-05-24T20:00:11.526Z
Price History Updated: 2026-05-25T05:33:12.549Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:33:12.549Z
Quant Updated: 2026-05-25T05:33:12.549Z
Sentiment Updated: 2026-05-25T05:33:12.549Z
Financials Status: current
Financials Updated: 2026-05-18T18:31:06.722Z
Financials Last Attempt: 2026-05-18T18:31:06.722Z
Financials Provider Tried: yahoo
Latest P&L Period: FY26
Latest Balance Sheet Period: FY26
Latest Cash Flow Period: FY26

## P&L (FY26)
Revenue: ₹287.23 Cr
Operating Profit: ₹48.63 Cr (OPM 16.93%)
Net Profit: ₹43.08 Cr
Tax: ₹14.44 Cr

## Annual P&L History
FY26: Rev ₹287.23Cr | PAT ₹43.08Cr | OPM 16.93%
FY25: Rev ₹268.72Cr | PAT ₹55.36Cr | OPM 15.98%
FY24: Rev ₹208.7Cr | PAT ₹22.46Cr | OPM 10.35%

## Balance Sheet (FY26)
Total Assets: ₹316.68 Cr
Total Liabilities: ₹40.51 Cr
Borrowings: ₹8.16 Cr
Cash: ₹10.04 Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Manish  Gupta, MD & Director
- Pratham  Rawal, Company Secretary & Compliance Officer
- Nirav Niranjanakumar Vora, Chief Financial Officer
- Amrut  Medhekar, Chief Operating Officer
- Sudeep  Paul, Vice President of Sales & Marketing

---
Source: rupiya.io/stocks/jagsnpharm
Disclaimer: For research and education only. Not investment advice.